SAN DIEGO, Feb. 6, 2018 /PRNewswire/ -- Neurocrine
Biosciences, Inc. (NASDAQ: NBIX) announced today that it will
report fourth quarter and year-end 2017 financial results after the
Nasdaq market closes on Tuesday, Feb. 13,
2018. Neurocrine will then host a conference call and
webcast to discuss its financial results and provide a Company
update that day at 2:00 p.m. Pacific
Time (5:00 p.m. Eastern
Time).
Participants can access the live conference call by dialing
888-632-3389 (US) or 785-424-1673 (International) using the
conference ID: NBIX. The webcast can also be accessed on
Neurocrine's website under Investors at http://www.neurocrine.com.
A replay of the webcast will be available on the website
approximately one hour after the conclusion of the event and will
be archived for one month.
About Neurocrine Biosciences, Inc.
Neurocrine
Biosciences is a San Diego based biotechnology
company focused on neurologic, psychiatric and endocrine related
disorders. The Company markets INGREZZA® (valbenazine)
capsules in the United States for the treatment of adults
with tardive dyskinesia. INGREZZA is a novel, selective
vesicular monoamine transporter 2 (VMAT2) inhibitor, and is the
first FDA approved product indicated for the treatment of adults
with tardive dyskinesia. The Company's three late-stage
clinical programs are: elagolix, a gonadotropin-releasing hormone
antagonist for women's health that is partnered with AbbVie
Inc.; opicapone, a novel, once-daily, peripherally-acting,
highly-selective catechol-o-methyltransferase inhibitor under
investigation as adjunct therapy to levodopa in Parkinson's
patients; and INGREZZA, a novel, once-daily, selective VMAT2
inhibitor under investigation for the treatment of Tourette
syndrome.
Neurocrine Biosciences, Inc. news releases are available through
the Company's website via the internet at
http://www.neurocrine.com.
View original
content:http://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-conference-call-and-webcast-of-fourth-quarter-and-year-end-2017-financial-results-300593725.html
SOURCE Neurocrine Biosciences, Inc.